Clinical Outcomes and Real-World Potential of Etrasimod in the Treatment of Ulcerative Colitis

By: Nower Chowdhury, PharmD Candidate c/o 2026, Anastasia Jairam, PharmD Candidate 2029, John Niewinski, PharmD Candidate 2028

INTRODUCTION

Ulcerative colitis (UC) is a chronic autoimmune condition that significantly impairs the quality of life for many individuals in the United States. In 2023, UC affected approximately 414 per 100,000 individuals nationwide. UC is a type of inflammatory bowel disease (IBD) characterized by inflammation that starts from the mucosal layer of the colon and can spread to the rectum and proximal colon. Among those affected, 32-46% experience moderate symptoms, while 13-14% have debilitating manifestations such as frequent diarrhea, loss of appetite, and severe rectal cramping.¹

In addition to gastrointestinal complications, UC can increase the risks of extraintestinal conditions such as respiratory disease, colorectal cancer, lymphoma, and skin cancer. Although the disease-specific mortality rate for UC remains low, the presence of comorbidities significantly elevates overall mortality risk. This highlights the need for effective, long-term therapies that can improve both disease control and quality of life.

Sphingosine-1-phosphate (S1P) receptor modulators have recently emerged as a novel class of oral small molecule therapy for UC, providing a targeted approach to immune modulation.² S1P receptors are membrane-bound lysophospholipid signaling molecules involved in lymphocyte trafficking.³ By modulating these receptors, S1P modulators can reduce the presence of lymphocytes at sites of gastrointestinal tissue, thereby reducing inflammatory responses.

The first S1P receptor modulator approved for clinical use was fingolimod, a non-selective agent indicated for multiple sclerosis. However, due to its lack of selectivity, fingolimod was associated with significant adverse effects, including cardiovascular complications and reduced pulmonary function. Ozanimod, a more selective S1P modulator, was later approved for both multiple sclerosis and UC, demonstrating an improved safety profile. However, ozanimod required a 7-day titration regimen, which delayed symptom relief for patients with active UC.

Etrasimod (marketed as Velsipity®) was developed to address the limitations of current UC therapies. While conventional treatments such as oral corticosteroids, TNFα antagonists, anti-integrin antibodies, anti-interleukin (IL)-12/23 agents, and Janus kinase (JAK) inhibitors remain widely used, many are associated with delayed onset of action, loss of efficacy over time, and the need for parenteral administration. These limitations highlight the need for safer, more convenient oral therapies with sustained clinical benefit. Etrasimod is a selective S1P receptor modulator with high affinity for S1P1, S1P4, and S1P5, and received FDA approval in October 2023 for the treatment of moderate to severe active UC. By preventing lymphocyte egress from lymph nodes into the bloodstream, etrasimod reduces intestinal inflammation and offers a once-daily oral alternative with a favorable safety profile.³

This paper will discuss the clinical development of etrasimod, with a focus on its mechanism of action, pivotal trial outcomes, safety considerations, and its emerging role in the treatment landscape for moderate to severe UC.

METHODS

Pfizer conducted multiple Phase III randomized, double-blind, and placebo-controlled trials to assess the safety and efficacy of etrasimod in patients with moderate to severe UC. Study participants included men and women aged 18-80 years diagnosed with moderate to severe UC, confirmed by endoscopic and histologic evidence. Furthermore, they must have displayed an inadequate, or lack thereof, response to approved therapies for ulcerative colitis. This included conventional therapies such as, TNFα antagonists, anti-integrin antibodies, anti–IL-12/23 antibodies, and JAK inhibitors.²

Notable exclusion criteria for the trial were severe extensive colitis and diagnosis of Crohn’s disease or intermediate colitis. Severe extensive colitis was indicated by a required colostomy or ileostomy within 12 weeks of trial randomization, complications like fulminant colitis, toxic megacolon, or bowel perforation, or a history of total or partial colectomy.³

ELEVATE UC 52 was conducted in 315 medical centers in 40 countries. 821 patients were enrolled, of which 433 underwent random assignment. The primary endpoint of UC 52 was the proportion of patients achieving clinical remission at weeks 12 and 52.³ Further, secondary endpoints included endoscopic improvement, symptomatic remission, and endoscopic improvement with histologic remission at weeks 12 and 52.³ They also assessed corticosteroid-free remission at week 52 and sustained clinical remission over time.

Trial ELEVATE UC 12 was performed amongst 407 centers in 37 countries, with 606 patients enrolled and 354 randomly assigned. The primary endpoint of UC 12 was clinical remission at week 12.³ Key secondary endpoints included the endoscopic improvement, symptomatic remission, and endoscopic improvement with histologic remission at week 12.³

In both trials, patients received either a 2 mg once-daily oral dose of etrasimod or a matching placebo in a 2:1 ratio under double-blind conditions. Treatment was not disclosed to investigators, study site staff, patients, sponsor personnel or study vendors involved with the conduct of the study.

The ELEVATE UC 52 trial lasted for 52 weeks, with a 12-week induction period followed by a 40-week maintenance period and a 4-week follow-up. After the initial 12-week period, patients could continue treatment into the 40-week period. Patients who felt their disease state had not improved or had worsened were allowed to terminate the treatment. Patients who completed the 52-week period were eligible to enroll in an open-label extension (OLE) study or participate in a 4-week follow-up visit.

The ELEVATE UC 12 trial was designed for a 12-week induction period followed by a 4-week follow-up. Similar to the ELEVATE UC 52 trial, patients could enroll in an OLE study after the induction period or participate in the follow-up period.

RESULTS & DISCUSSION

In ELEVATE UC 52, a significantly greater proportion of patients in the etrasimod group achieved clinical remission than patients in the placebo group at both 12-week induction period (27% vs. 7%) and at week 52 (32% vs. 7%).³ Similarly, ELEVATE UC 12 showed that 25% of patients in the etrasimod group were in clinical remission at week 12 compared to 15% in the placebo group at the end of the 12-week induction period.³

Key secondary endpoints also demonstrated the efficacy of etrasimod, including endoscopic improvement, symptomatic remission, and endoscopic-histologic remission. In ELEVATE UC 52, 32% of patients reached corticosteroid-free remission by week 52, and 18% of patients experienced sustained remission during weeks 12 and 52.³ Symptom improvement was observed starting at week 2 in ELEVATE UC 52 and week 4 in ELEVATE UC 12.

These findings suggest that etrasimod serves as an effective induction and maintenance therapy for patients with moderate to severe UC. The continuous “treat-through” design of ELEVATE UC 52 closely mirrors clinical practice, allowing for a more realistic assessment of long-term treatment benefit. The increase in clinical remission from week 12 to week 52 indicates that some patients experience a delayed yet sustained response with continued therapy, reinforcing the value of long-term treatment adherence. Efficacy was observed across both treatment-naive and treatment-experienced subgroups. Treatment-experienced patients exhibited slightly decreased treatment effect, similar to how patients taking other alternative advanced therapies respond. Overall, etrasimod can be considered a suitable therapeutic choice compared to available biologics and small molecules with once-daily oral dosing, rapid onset of action, and ability to induce steroid-free remission.

SAFETY

The safety profile of etrasimod suggests it is generally well tolerated. In ELEVATE UC 52, adverse events (AEs) were reported in 71% of patients receiving etrasimod compared to 56% in the placebo group.³ The most frequently reported AEs included anemia, headache, and worsening of UC. Most AEs were mild or moderate in severity. Serious AEs (SAEs) like bradycardia and macular edema were less common and comparable between groups (7% in etrasimod vs 6% in placebo), suggesting cardiac and ophthalmologic monitoring for the S1P modulator drug class. The absence of significant differences in SAEs between treatment groups supports the overall tolerability of etrasimod in a real-world clinical setting

CONCLUSION

Etrasimod presents as a promising advancement in the treatment of moderate to severe ulcerative colitis. Etrasimod was shown to significantly improve outcomes of clinical remission, endoscopic outcomes, symptomatic relief, and steroid-free remission compared to placebo in pivotal Phase III trials. Its once-daily oral administration and favorable pharmacokinetics and safety profile makes it an appealing alternative to existing S1P modulators and biologics in both induction and maintenance phases.

Given its recent FDA approval and entry into clinical practice, etrasimod should further be explored for its long-term impacts on patient quality of life, health economics, medication adherence, and payer reimbursement models to better define its place in real-world care. Continued post-marketing surveillance and real-world evidence will also be essential in confirming these findings across broader, more diverse patient populations.

REFERENCES

1. Canadian Agency for Drugs and Technologies in Health (CADTH). Etrasimod (Velsipity): Reimbursement Review. Ottawa, ON: CADTH; December 2024. SR0795_Velsipity_Combined_Review.
2. Bencardino S, D’Amico F, Faggiani I, et al. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. J Clin Med. 2023;12(15):5014. Published 2023 Jul 30. doi:10.3390/jcm12155014
3. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 2023;0(0). doi:https://doi.org/10.1016/S0140-6736(23)00061-2